JC10 Rec'd PCT/PTO 2 0 JUN 2005

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE REV. 2/01T					OMER NO. 22,852 ATTORNEY'S DOCKET NUMBER				
TRANSMITTAL LETTER TO THE UNITED STATES 09617.0001									
DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO.									
:			NG A FILI	(If known, see 37CFR1.5) ##4 10/510,627					
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE April 9, 2003					PRIORITY DATE CLAIMED April 9, 2002				
I	TITLE OF INVENTION								
			IG LEUKEM	IA, PRE-LEUKEMIA OR ALEUKEMI	IC MALIGNANT BLOOD				
			NOSTIC THE						
		FOR DO							
				Chie ITO Hidenao SATO Akiko FU	RUYA Kenya SHITARA Sejiji				
Kiyoshi ANDO, Tomomitsu HOTTA, Chie ITO, Hidenao SATO, Akiko FURUYA, Kenya SHITARA, Seiji SUGIMOTO, Hiroaki KOHNO									
Applicar	nt(s) herev	vith submit	ts to the United	States Designated/Elected Office (DO/EO/US) th	e following items and other information:				
1.		This is a	FIRST submiss	ion of items concerning a filing under 35 U.S.C	371.				
2.	\boxtimes	This is a	SECOND or SI	JBSEQUENT submission of items concerning a	filing under 35 U.S.C. 371.				
3.			This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4.		The US I	has been elected	by the expiration of 19 months from the priority	date (Article 31).				
5.		A copy o	of the Internation	al Application as filed (35 U.S.C. 371 (c)(2)).					
		a.	☐ is att	ached hereto (required only if not communicated	by the International Bureau.				
		b.		een communicated by the International Bureau.					
		c.		t required, as the application was filed with the U	Inited States Receiving Office (RO/US).				
6.		An Engli		slation of the International Application as filed (_				
		a.		ached hereto.					
		b.	☐ has b	een previously submitted under 35 U.S.C. 154 (d)(4).				
7.		Amendm		ns of the International Application under PCT Ar					
		a.		ttached hereto (required only if not communicate					
		b.							
		c.		not been made; however, the time limit for maki					
		d.		not been made and will not be made.					
8.		An Engli	ish language trar	slation of the amendments to the claims under P	CT Article 19 (35 U.S.C. 371 (c)(3)).				
9.		-		the inventor(s) (35 U.S.C. 371 (c)(4)).	, , , , , , , , , , , , , , , , , , , ,				
10.		An English language translation of the annexes of the International Preliminary Examination Report under PCT							
]		Article 36 (35 U.S.C. 371 (c)(5)).							
Items 1	1 to 20 be	low conce	rn document(s)	or information included:					
11.		Informat	ion Disclosure 9	Statement under 37 CFR 1.97 and 1.98					
12.				t for recording. A separate cover sheet in compli	ance with 37 CFR 3 28 and 3 31 is				
12.		included		tion recording. A separate cover sheet in compi	ance with 57 Cr R 5.26 and 5.51 is				
13.		A FIRST preliminary amendment.							
14.		A SECOND or SUBSEQUENT preliminary amendment.							
15.		A Substitute specification.							
16.		A change of power of attorney and/or address letter.							
17.	\boxtimes	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.							
18.		A second copy of the published international application under 35 U.S.C. 154 (d)(4).							
19.		A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).							
20.									
		a.	☐ Copy	of cover page of International Publication No. V	WO 03/085399 A1				
		b.		of Notification of Missing Requirements.					
		c.		ence Listing in Written form consisting of 8 shee	ets				
[d	⊠ State	ment Under 37 CFR & 1 821					

	APPLICATION NO. (If known, see 37CFR 1.5) INTERNATIONAL APPLICATION NO.						ATTORNEY'S DOCKET NUMBER			
10/51	10/510,627			PCT/JP03/0453	31	09617.0001				
21. 🛭	The follo		CALCULATIONS P	TO USE ONLY						
. BASI	C NATIONA	AL FEE (37 CFR 1.492 (a)	(1) - (5)): '	3					
nor in	ternational se	arch fee (37 CFR 1.445(a)(ation fee (37 CFR 1.482) 45(a)(2)) paid to USPTO ared by the EPO or JPO\$1110.00						
				CFR 1.482) not paired by the EPO or J			\$950.00			Landy and the second se
				CFR 1.482) not paid to 1.445(a)(2)) paid to		ro	\$790.00			
				CFR 1.482) paid to Γ Article 33(1)-(4)			\$750.00			
				CFR 1.482) paid to PCT Article 33 (1)-(\$100.00			
			•	ENTER APPR	OPRI	ATE BASIC FE	E AMOUNT =	\$		
				or declaration later to (37 CFR 1.492 (e))		□ 20	⊠ 30	\$130.00		
C	CLAIMS	NUM	IBER FILED	NUMBER EXTR	RA	RA1	ГЕ			1
Total	Claims	45	- 20 =	25		x \$18	3.00	\$		1
Indepe	endent Claims	11	-3 =	8		x \$88	3.00	\$		1
MULT	TIPLE DEPENI	DENT CLA	AIM(S) (if applicable	e)		+\$300	0.00	\$		
				TOTAL O	FTHE	E ABOVE CALO	CULATIONS =	\$130.00		
□ A _I	plicant claim	s small en	tity status. See 3'	7 CFR 1.27. The fe	ees ind	licated above are	reduced by ½.	\$		
			·				SUBTOTAL =	\$130.00		
			r furnishing the E rity date (37 CFR	nglish translation la 1.492(f)).	ater tha	an 🗌 20	□ 30	\$		
						TOTAL NAT	IONAL FEE =	\$130.00		
				CFR 1.21 (h)). Th		gnment must be a	ccompanied by +	\$		
2005 LLAI	NDGRA 000000	21 105106	627			TOTAL FEES	ENCLOSED =	\$130.00		
1617		1	130.00 OP					Amount to be refunded:	\$	
								charged:	\$	
								_		
b.	☐ Please of A dupli	f\$	to cover the abov	e fees.						
c.				orized to charge any A duplicate copy of			may be required,	or credit any ove	rpayment to	
d.				ard. WARNING: ed on this form. P						
must	be filed and g	ranted to		37 CFR 1.494 or 1 ation to pending sta		160			7 (a) or (b))	
	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.					MULA //R	WEST W	331		
901 1	01 New York Avenue, N.W. SIGNATURE				/					
Wasl	nington, D.C	. 20001-4	4413		Е	rnest F. Chapma	an ,		·	
DAT	ED: June 20	. 2005			N	AME/REGISTR	ATION NO. 25,	961		
		,								



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. 1450 Alexandra, Viginia 22313-1450 www.usplu.gov

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO. 10/510,627 09617.0001

Kivoshi Ando

INTERNATIONAL APPLICATION NO.

PCT/JP03/04531

LA. FILING DATE PRIORITY DATE

04/09/2003

04/09/2002

22852 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP 901 NEW YORK AVENUE, NW **WASHINGTON, DC 20001-4413**

CONFIRMATION NO. 4183 371 FORMALITIES LETTER *OC000000015761186*

Date Mailed: 04/18/2005

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 10/08/2004
- English Translation of the IA filed on 10/08/2004
- Copy of the International Search Report filed on 10/08/2004
- Copy of IPE Report filed on 10/08/2004
- Information Disclosure Statements filed on 10/08/2004
- Biochemical Sequence Diskette filed on 10/08/2004
- Biochemical Sequence Listing filed on 10/08/2004
- U.S. Basic National Fees filed on 10/08/2004
- Priority Documents filed on 10/08/2004

FINNEGAN HENDERSON, FARABOW, GARRETT AND DUNNER, LLP

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- \$130 Surcharge for providing the oath or declaration later than 30 months from the priority date (37 CFR 1.492(e)) is required.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

\$130 Late oath or declaration Surcharge.



A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

WINSTON M ALVARADO

Telephone: (703) 308-9140 EXT 206

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/510,627	PCT/JP03/04531	09617.0001

FORM PCT/DO/EO/905 (371 Formalities Notice)



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/5/0

Source:

Date Processed by STIC:

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
 - 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
 U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04

Mase mail this report with the 905.

Nington Alvaredo National Stage Processing Paralagai Spacialist (703) 365-6421



RAW SEQUENCE LISTING

DATE: 10/16/2004

PATENT APPLICATION: US/10/510,627

TIME: 08:51:44

Input Set : N:\FATIMA\10510627.txt

Output Set: N:\CRF4\10162004\J510627.raw

3 <110> APPLICANT: TOKAI UNIVERSITY

KYOWA HAKKO KOGYO CO., LTD.

KYOWA MEDEX CO., LTD.

7 <120> TITLE OF INVENTION: A diagnostic method and a diagnostic agent for

leukemia, preleukemia and leukemic malignant hemopathy

10 <130> FILE REFERENCE: 11470WO1

C--> 12 <140> CURRENT APPLICATION NUMBER: US/10/510,627

C--> 13 <141> CURRENT FILING DATE: 2004-10-08

15 <150> PRIOR APPLICATION NUMBER: JP P2002-106786

16 <151> PRIOR FILING DATE: 2002-04-09

18 <160> NUMBER OF SEQ ID NOS: 11

20 <170> SOFTWARE: PatentIn Ver. 2.1

lose Not Comply ected Diskette Needer

ERRORED SEQUENCES

270 <210> SEQ ID NO: 11

271 <211> LENGTH: 18

272 <212> TYPE: DNA

273 <212 ORGANISM: Artificial Sequence
W--> 275 (220) FEATURE:

W--> 275 223 OTHER INFORMATION:

W--> 275 < 400 > 11

276 ttttgggggc tttggtgg

E--> 288 /8/8

7 see p. 2 for evor exploration

RAW SEQUENCE LISTING ERROR SUMMARY PATENT APPLICATION: US/10/510,627 DATE: 10/16/2004 TIME: 08:51:45

Input Set : N:\FATIMA\10510627.txt

Output Set: N:\CRF4\10162004\J510627.raw

Use of <220> Feature (NEW RULES):

Sequence(s) __are missing the <220> Feature and associated headings. Use of <220 to <223 is MANDATORY if <213 ORGANISM is "Artificial Sequence" or "Unknown". Please explain source of genetic material in <220> to <223> section (See "Federal Register," 6/01/98, Vol. 63, No. 104,pp.29631-32) Iach of these sequences has the above enou

(Sec.1.823 of new Rules)

sel p. 3 for more enou

.. Ala Leu Gly Leu Pro Ala Gly Arg Gly Asp Glu Asn Pro Ala Gly Thr

do not show page humbers in the computer readable file of the Sequence Listing (per 1.824 of Seguera Rules, Jegveru Lesterj

VERIFICATION SUMMARY PATENT APPLICATION: US/10/510,627

DATE: 10/16/2004 TIME: 08:51:45

Input Set : N:\FATIMA\10510627.txt

Output Set: N:\CRF4\10162004\J510627.raw

L!12 M:270 C: Current Application Number differs, Replaced Application Number L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:228 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0 L:247 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ#:8, <213> ORGANISM: Artificial Sequence L:247 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:8, <213> ORGANISM: Artificial Sequence L:247 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:8,Line#:247 L:252 M:259 W: Allowed number of lines exceeded, <210> SEQ ID NO L:257 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ#:9, <213> ORGANISM: Artificial Sequence L:257 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:9, <213> ORGANISM: Artificial Sequence L:257 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:9,Line#:257 L:266 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ#:10, <213> ORGANISM: Artificial Sequence L:266 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:10, <213> ORGANISM: Artificial Sequence

L:266 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:10,Line#:266

L:275 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ#:11, <213> ORGANISM: Artificial Sequence

L:275 M:258 W: Mandatory Feature missing, <223> Tag not found for SEQ#:11, <213> ORGANISM: Artificial Sequence

L:275 M:258 W: Mandatory Feature missing, <223> Blank for SEQ#:11,Line#:275

L:288 M:254 E: No. of Bases conflict, LENGTH:Input:8 Counted:19 SEQ:11

L:288 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:2

L:288 M:252 E: No. of Seq. differs, <211> LENGTH:Input:18 Found:19 SEQ:11